Clinical Trials Logo

Clinical Trial Summary

Epilepsy is a frequent cause of morbidity in the pediatric age group. Many catastrophic epilepsies present during infancy and childhood1. Seizures in these epileptic disorders are difficult to control; sometimes only at the expense of multiple and toxic levels of antiepileptic medications. The shortcomings of antiepileptic drug therapy and epilepsy surgery warrants the need for alternative treatments. Ketogenic diet is effective for refractory epilepsies (33% of patients with refractory epilepsy have more than 50% reduction in seizures from the baseline and 15-20% become seizure free) and has gained widespread acceptance. Low glycemic index diet treatment (LGIT) is designed as a variant of ketogenic diet. There are retrospective studies on LGIT in childhood refractory epilepsy reporting seizure reduction comparable to that of patients on ketogenic diet. There have been no randomized controlled trials assessing the efficacy of the low glycemic index diet in refractory epilepsy. In this study we plan to assess the efficacy of LGIT among children with drug refractory epilepsy.


Clinical Trial Description

Each patient will undergo detailed clinical evaluation according to a structured proforma. Seizure type, frequency, age at onset, perinatal details, family history, developmental status and treatment history will be recorded. Corticosteroids or ACTH (if patient is already on) would be tapered off 2 weeks before starting LGIT. All co-medications will be changed to carbohydrate free preparations, wherever available only in the intervention group.

Eligible patients will be randomized in to two groups: the intervention and the control arm. Both groups will undergo a baseline four week observation period, during which parents will be asked to maintain a daily seizure log; recording seizure type, duration and frequency. In the intervention arm, the children will be started on low glycemic index diet after this 4-week baseline period. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented. The drop out from the intervention group will be documented along with the reason for the same. At the end of the 3 month study period patient in the intervention arm will be continued with the LGIT but that will not come under the purview of this study. At the end of three months study period, patients in the control arm will be offered the option of low glycemic index diet treatment.

Low glycemic index diet administration

1. Three day food intake by recall method will be documented

2. The calorie requirement would be calculated as per the recommended daily allowance (RDA) for the ideal weight for that age

3. Diet regime will be explained to the parents

4. Patients (wherever applicable) and their parents will be given diet counseling

5. LGIT will be started on out patient basis.

6. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items33. They will also be given a list of food items (medium and high glycemic index) which should be avoided. (Appendix)

7. Total carbohydrates intake will be restricted to 10% of caloric intake/ day (maximum 40-60 g/day).

8. Carbohydrate values of various food items will be explained in detail, and carbohydrate exchange lists will be provided to the parent. Three to four 15 gram carbohydrate exchanges will be allowed in a day. (Appendix)

9. Fats (e.g. cream, butter, oils and ghee) can be taken by the patient without any restriction.

10. Proteins intake will be allowed up to 30% of the total caloric intake per day (cheese, fish, eggs, chicken and soya products).

11. Sample menu will be discussed with the parent.

12. Clear carbohydrate free fluids will not be restricted.

Follow up Children will be reviewed as outpatients at 1, 2 and 3 months. A three day dietary intake chart will be reviewed at each visit to compute calorie and carbohydrate intake, and to evaluate and reinforce compliance with the prescribed diet. Weight will be checked at each visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01645072
Study type Interventional
Source All India Institute of Medical Sciences, New Delhi
Contact Sheffali Gulati, MD
Phone +91-11-26594679
Email sheffaligulati@gmail.com
Status Unknown status
Phase Phase 3
Start date June 2011
Completion date October 2012

See also
  Status Clinical Trial Phase
Completed NCT02866240 - Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy N/A
Withdrawn NCT04753983 - A Study to Evaluate fMRI of Active DBS Stimulation in Epilepsy N/A
Completed NCT01899898 - Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05493722 - Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy Early Phase 1
Recruiting NCT03062514 - Trial to Evaluate the Safety and Effectiveness of Vagus Nerve Stimulation for Children With Refractory Epilepsy N/A
Recruiting NCT04770337 - Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy N/A
Recruiting NCT05232630 - Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes Phase 4
Completed NCT04545346 - The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy N/A
Not yet recruiting NCT04542629 - Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children Phase 4
Terminated NCT03570489 - Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy: N/A
Completed NCT05031208 - Acute and Long Term Effects of VNS on Memory in Patients With Refractory Epilepsy N/A
Completed NCT01880333 - Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy Phase 2/Phase 3
Completed NCT03676569 - Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy Phase 1
Withdrawn NCT03115489 - Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus Phase 2/Phase 3
Completed NCT02876289 - Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon) N/A
Completed NCT01521754 - Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
Recruiting NCT04684797 - Localization of the Reward Positivity to ACC N/A
Completed NCT05292183 - Modulation of Emotion Perception in Humans Via Amygdala Stimulation N/A
Terminated NCT04398667 - European Non-interventional Study on Refractory Epilepsy With Developmental Delay
Active, not recruiting NCT04218812 - Clinical Utility of Automated Electric Source Imaging in Presurgical Evaluation N/A